JP2025505294A - Ｌ－トリプトファン、ｌ－５－ヒドロキシトリプトファンおよび末梢分解阻害剤を含む医薬組成物および医薬 - Google Patents

Ｌ－トリプトファン、ｌ－５－ヒドロキシトリプトファンおよび末梢分解阻害剤を含む医薬組成物および医薬 Download PDF

Info

Publication number
JP2025505294A
JP2025505294A JP2024548458A JP2024548458A JP2025505294A JP 2025505294 A JP2025505294 A JP 2025505294A JP 2024548458 A JP2024548458 A JP 2024548458A JP 2024548458 A JP2024548458 A JP 2024548458A JP 2025505294 A JP2025505294 A JP 2025505294A
Authority
JP
Japan
Prior art keywords
tryptophan
hydroxytryptophan
pharmaceutical composition
pharma
peripheral degradation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024548458A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025505294A5 (cg-RX-API-DMAC10.html
Inventor
カンプラード，ヨアヒム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2025505294A publication Critical patent/JP2025505294A/ja
Publication of JP2025505294A5 publication Critical patent/JP2025505294A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
JP2024548458A 2022-02-16 2023-02-08 Ｌ－トリプトファン、ｌ－５－ヒドロキシトリプトファンおよび末梢分解阻害剤を含む医薬組成物および医薬 Pending JP2025505294A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102022103658.8 2022-02-16
DE102022103658.8A DE102022103658A1 (de) 2022-02-16 2022-02-16 Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer
PCT/EP2023/053129 WO2023156275A1 (en) 2022-02-16 2023-02-08 Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor

Publications (2)

Publication Number Publication Date
JP2025505294A true JP2025505294A (ja) 2025-02-21
JP2025505294A5 JP2025505294A5 (cg-RX-API-DMAC10.html) 2026-02-03

Family

ID=85221827

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024548458A Pending JP2025505294A (ja) 2022-02-16 2023-02-08 Ｌ－トリプトファン、ｌ－５－ヒドロキシトリプトファンおよび末梢分解阻害剤を含む医薬組成物および医薬

Country Status (10)

Country Link
US (1) US20250161270A1 (cg-RX-API-DMAC10.html)
EP (1) EP4479027A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025505294A (cg-RX-API-DMAC10.html)
KR (1) KR20240152875A (cg-RX-API-DMAC10.html)
CN (1) CN118871096A (cg-RX-API-DMAC10.html)
AU (1) AU2023222362A1 (cg-RX-API-DMAC10.html)
CA (1) CA3243635A1 (cg-RX-API-DMAC10.html)
DE (1) DE102022103658A1 (cg-RX-API-DMAC10.html)
MX (1) MX2024009966A (cg-RX-API-DMAC10.html)
WO (1) WO2023156275A1 (cg-RX-API-DMAC10.html)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4126672A (en) 1976-02-04 1978-11-21 Hoffmann-La Roche Inc. Sustained release pharmaceutical capsules
US4167558A (en) 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4140755A (en) 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
CH652025A5 (de) 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
DE3642668A1 (de) 1986-12-13 1988-06-23 Kamprad Joachim Schmerzmittel fuer menschen
FR2654931B1 (fr) 1989-11-24 1993-08-27 Trouillas Paul Compositions pharmaceutiques possedant une activite sur l'ataxie et les troubles de l'equilibre, cerebelleux ou autres, de toutes origines, comprenant l'association de l-5-hydroxytryptophane et de carbidopa.
US6207699B1 (en) * 1999-06-18 2001-03-27 Richard Brian Rothman Pharmaceutical combinations for treating obesity and food craving
EP1751312A4 (en) * 2004-05-21 2010-01-27 Univ Duke POLYMORPHISM IN TRYPTOPHAN HYDROXYLASE 2 REGULATING BRAIN SEROTONIN SYNTHESIS
DE102004039196B4 (de) 2004-08-12 2008-07-31 Dr.Kamprad Kg Neue Formulierung für L-Tryptophan
US20060257469A1 (en) * 2005-04-05 2006-11-16 Bulka Yochanan R Enhanced indoleamine and catecholamine bio-availability via catechin inhibition of L-Dopa decarboxylase
ES2948788T3 (es) * 2018-01-29 2023-09-19 Univ Duke Composiciones y métodos para mejorar la biodisponibilidad del 5-hidroxitriptófano

Also Published As

Publication number Publication date
WO2023156275A1 (en) 2023-08-24
CA3243635A1 (en) 2023-08-24
DE102022103658A1 (de) 2023-08-17
EP4479027A1 (en) 2024-12-25
AU2023222362A1 (en) 2024-09-12
CN118871096A (zh) 2024-10-29
KR20240152875A (ko) 2024-10-22
US20250161270A1 (en) 2025-05-22
MX2024009966A (es) 2024-11-08

Similar Documents

Publication Publication Date Title
US11773051B2 (en) S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same
US20220378731A1 (en) Composition For Treating Tauopathy In The Brain, Brain Stem and Spinal Column
JP2024019691A (ja) 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
ZA200700395B (en) Novel formulation for L-tryptophane comprising carbidopa/benserazide
JP2004534094A (ja) 二日酔いに有効な組成物及びそのための使用
CN102014896A (zh) 包含西坦和肉毒碱的药物组合物及其制备方法
CA2382548C (en) Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof
US20110117070A1 (en) Compositions and methods for treating headache
EP4479027A1 (en) Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor
EP4665327A1 (en) Compositions comprising 3,4-methylenedioxymethamphetamine, optionally in combination with n-acylethanolamines, and uses thereof
JP2025505294A5 (cg-RX-API-DMAC10.html)
US20050059741A1 (en) Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-1
KR20060094875A (ko) 코엔자임 큐텐을 유효 성분으로 함유하는 알코올성 장애의제거 및 완화제용 약학적 조성물과 그의 복용 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260120